Almirall and Shenzhen CrystalO Biopharma Technology have entered into a collaboration and licensing agreement to advance AI- and structure-based drug discovery for medical dermatology. The partnership will combine CrystalO’s expertise in ion channel target discovery and small-molecule drug development with Almirall’s experience in dermatology research, clinical development, regulatory activities, and global commercialization. Under the agreement, CrystalO will use its AI-powered drug discovery platform to support candidate discovery, optimization, IND-enabling studies, and early clinical development through proof-of-concept testing. Under the agreement, CrystalO will receive an upfront payment from Almirall, and is also eligible to receive success-based payments tied to research, development, regulatory and commercial milestones, as well as tiered royalties based on future net sales of the product.
Also Read: ZeroTier Partners with Carahsoft to Expand Quantum-Secure Networking for the Public Sector
“This collaboration with CrystalO marks another important step in advancing our innovation strategy in China and further reinforces our strong R&D pipeline in medical dermatology. We look forward to the potential this discovery partnership holds for delivering meaningful benefits to patients living with skin conditions worldwide,” commented Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall. Working together also showcases the increasing impact that AI is having in the drug discovery and development process and supports mostly both companies’ endeavours to develop better and more effective therapies for sufferers of skin diseases.
